SOM 0777

Drug Profile

SOM 0777

Alternative Names: JLB 137; SOM 0777

Latest Information Update: 27 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SOM Biotech
  • Class Small molecules
  • Mechanism of Action Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Glioblastoma

Most Recent Events

  • 31 Jan 2016 SOM 0777 is available for licensing as of 31 Jan 2016.
  • 31 Jan 2016 Preclinical trials in Glioblastoma in Spain (PO) before January 2016
  • 31 Jul 2013 SOM 0777 licensed to Argon Pharma for the treatment of Glioblastoma (SOM Biotech website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top